Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending March 2014, with the report dated April 14, 2014. The filing serves as a notification of transactions involving directors, persons discharging managerial responsibility (PDMRs), or connected persons, specifically regarding the GSK 401K plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific personnel transactions rather than a financial performance report.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The only change noted is an increase in the notional allocation of American Depositary Shares (ADSs) within the GSK 401K plan following a revaluation of the cash element.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly details a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(c).
Important Facts for Investors
- Transaction Type: Increase in notional ADS allocation within the GSK 401K plan.
- Transaction Date: April 11, 2014.
- Price per ADS: $51.76.
- Individuals Involved: Dr. M. Slaoui (Director/PDMR) had no change; Dr. K. Slaoui (Connected Person) received an allocation of 5 ADSs.
- Financial Data: No financial performance data is included in this specific filing.